KEI comments on Tibotec voluntary licenses of a new HIV-AIDS product
Today, Tibotec, a subsidiary of Johnson & Johnson, announced it has signed voluntary licensing agreements with several Indian and South African generic companies to allow generic competition on a new HIV-AIDS treatment, the investigational non-nucleoside reverse transcriptase inhibitor rilpivirine hydrochloride (TMC278) (rilpivirine hydrochloride), to certain developing countries. Continue Reading